This "Specialty Testing" webinar describes a new serum test for bile acid malabsorption. Descriptions illustrate how the test can be used as a screening test and as a tool for therapeutic action.
As a senior principal developer for the brand-new Process Innovation Through Automation Laboratory, Brian Dukek helps labs throughout the Department of Laboratory Medicine and Pathology evaluate new automation tools and streamline automation workflows.
As a national accounts executive for Mayo Clinic Laboratories, Kimberly Knight helps clients see and understand the importance of laboratory testing and how partnering with Mayo Clinic Laboratories on that testing can help them and their patients.
Mayo Clinic Laboratories is committed to working with our communities as we all face the unprecedented challenges of the COVID-19 pandemic. Since early 2020, Mayo Clinic researchers and experts have provided expertise to guide the public health response, and our clinical staff has been on the front lines providing lifesaving care for patients with COVID-19.
Matt Millen, ex-pro NFL player, who played on four Super Bowl-winning teams underwent a nearly six-year medical journey in search for answers. Finally, he was diagnosed with amyloidosis using a new testing methodology at Mayo Clinic.
Understanding the difference between benign and malignant adrenal tumors has always been difficult, but the new Urinary Steroid Profile assay will assist with this medical challenge.
Fewer than half the people found to have colorectal cancer are diagnosed at an early stage, when treatment is most effective. New therapies can reduce tumor size and prolong life, but they can also be costly and not work as intended. The results and interpretations from our laboratories provide clinically actionable results to guide treatment selection, ensuring every patient receives the medication most appropriate for care. In addition to guiding treatment, our testing also assesses risk for developing hereditary cancer syndrome.
Newborn screening panels that test for a variety of conditions are available in every state; however, test performance and response rate by each state are very different. Mayo Clinic's Biochemical Genetics Laboratory created the Collaborative Laboratory Integrated Reports tool to mitigate the national (and international) problem of false positives and to raise the bar on test performance.
Using advanced technology, scientists at Chan Zuckerberg (CZ) Biohub, Mayo Clinic and University of California, San Francisco (UCSF), have discovered an autoimmune disease that appears to affect men with testicular cancer.
Mayo Clinic Laboratories is the only laboratory in the world to offer testing for a novel form of autoimmune meningoencephalomyelitis. Known as autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy, the condition was identified by Mayo Clinic in 2016. The GFAP antibody test is offered as part of Mayo Clinic Laboratories’ encephalitis and myelopathy evaluations.
Mayo Clinic Laboratories is one of the few laboratories in the country to offer two special sequencing-based tests for bacteria in its catalog. The first test is designed to help protect patients by investigating potential outbreaks of a single bacterial species or by identifying recurrent infections in an individual patient. The second has the ability to detect DNA of any bacteria to help identify the cause of an infection.
Blacklegged ticks (also known as deer ticks) are turning up more frequently in Minnesota, and so are the diseases they carry. Bobbi Pritt, a parasitologist in the Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester, Minnesota, weighs in on the issue.
Cytomegalovirus, or CMV, is a common cause of disease in the transplant population. In some patients who are diagnosed with CMV and are on antiviral treatment for infections, the virus may develop resistance to the drugs. This “Hot Topic” will provide an overview of a new test developed by Mayo Clinic Laboratories, which uses next-generation sequencing technology to identify mutations in the genome of CMV that may be associated with antiviral resistance.